About Us.

We are advancing a next-generation treatment platform that combines innovative drug formulation with a proprietary digital combination prescription safety system— creating a complete, safety-first platform solution for the delivery of ketamine in conditions such as: 

Treatment-Resistant Major Depressive Disorder (TRMDD) 

Treatment-Resistant Bipolar II Depression (TRBPD-II) 

By embedding FDA-aligned REMS (Risk Evaluation and Mitigation Strategy) principles into our platform from day one, we are setting a new standard for how mood disorder therapies can be delivered responsibly, effectively, and at scale. 

At Neurocentrx, we take a safety-first approach to improving access for established mental health prescriptions. That’s why we’ve developed a model that integrates: 

A pharmacologically optimized oral ketamine capsule with abuse deterrence built in 

A digital safety platform to ensure that patients and psychiatrists will access regulated prescription care tools, to offer a reliable transition to home-based care settings 

A clinic-to-home dosing pathway, that migrates structured and well-supported prescription safety measures into a preferred home setting, to maintain regulatory assurances within patient-oriented care.

Our innovation approach aims to significantly improve access to care, while preventing prescription misuse and ensuring medication controls. In total, we believe our product and care delivery model may lower access inequalities, provide care at more sustainable costs, all while preserving the efficacy of a proven molecule. 

We envision a future where life-changing mental health treatments don’t require clinical care forever — where prescription care management can become both patient-centered but community-assured. Through our combined pharmaceutical and digital innovation, we aim to: 

Move clinical care standards into home-based care settings

Enhancing mental healthcare delivery 

Supporting global access to evidence-based therapies